etopophos and japanese-encephalitis-virus-vaccine-sa14-14-2 Interactions

You searched for interactions between:

• etopophos
• japanese-encephalitis-virus-vaccine-sa14-14-2 (Japanese encephalitis virus vaccine SA14-14-2)

Interaction(s) found:

etoposide phosphate and Japanese encephalitis virus vaccine SA14-14-2 (Moderate Drug-Drug)

MONITOR: The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day or 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), or long-term topical or inhaled corticosteroids.

MANAGEMENT: In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. However, higher dosages or more frequent boosters may be required in some cases. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).